Overview TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis Status: Completed Trial end date: 2003-02-01 Target enrollment: Participant gender: Summary Randomized, double-blind study of the tolerability of three different doses of rifapentine Phase: Phase 2 Details Lead Sponsor: Centers for Disease Control and PreventionCollaborators: US Department of Veterans AffairsVA Office of Research and DevelopmentTreatments: RifampinRifapentine